Literature DB >> 25900160

Candida biomarkers in patients with candidaemia and bacteraemia.

M Carmen Martínez-Jiménez1, Patricia Muñoz2, Maricela Valerio1, Roberto Alonso1, Carmen Martos3, Jesús Guinea4, Emilio Bouza5.   

Abstract

OBJECTIVES: Microbiological strategies are necessary to help clinicians discontinue empirical antifungal therapy in patients with suspected invasive candidiasis. Culture methods and biomarkers each show low sensitivity. We analysed the value of combining different biomarkers as a decision-making tool for discontinuing empirical antifungal treatment.
METHODS: We studied stored serum samples from 31 patients with candidaemia (Candida albicans 40%, Candida tropicalis 20%, Candida parapsilosis 18%, Candida glabrata 12% and other 10%) and 50 patients with bacteraemia at Gregorio Marañón Hospital, Madrid, Spain. C. albicans germ tube antibody (CAGTA), mannan antigens (MN), antimannan antibodies (AMN) and (1→3)-β-d-glucan (BDG) were assayed using the manufacturer's and alternative cut-offs to improve the accuracy of the tests.
RESULTS: The sensitivity of the biomarkers when used alone was low (58%-84%), but specificity was high (65.8%-92.0%). The best combinations were CAGTA and BDG using cut-offs of 1/80 and 80 pg/mL, respectively (sensitivity 96.8% and specificity 84%), and CAGTA and MN using cut-offs of 1/80 and 75 pg/mL, respectively (sensitivity 93.5% and specificity 86.0%). The sensitivity of both combinations was 100% for C. albicans, C. tropicalis and C. parapsilosis, but only combinations including BDG detected Candida krusei. The negative predictive values (NPVs) of both combinations were, respectively, 97.7% and 95.6% (prevalence of candidaemia, 23.6%). For a prevalence of candidaemia of 5% and 10%, the NPV reached 99.8% and 99.6%.
CONCLUSIONS: The combinations of CAGTA and BDG or CAGTA and MN had a very high NPV at the alternative cut-offs and could be used in antifungal stewardship programmes as a decision-making tool for discontinuing unnecessary empirical therapy in patients with suspected candidaemia.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antifungal therapy; diagnosis; stop; unnecessary antifungals

Mesh:

Substances:

Year:  2015        PMID: 25900160     DOI: 10.1093/jac/dkv090

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Optimized Use of the MALDI BioTyper System and the FilmArray BCID Panel for Direct Identification of Microbial Pathogens from Positive Blood Cultures.

Authors:  B Fiori; T D'Inzeo; A Giaquinto; G Menchinelli; F M Liotti; F de Maio; G De Angelis; G Quaranta; D Nagel; M Tumbarello; B Posteraro; M Sanguinetti; T Spanu
Journal:  J Clin Microbiol       Date:  2015-12-16       Impact factor: 5.948

2.  Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship.

Authors:  Maricela Valerio; Antonio Vena; Carmen Guadalupe Rodríguez-González; Esther Chamorro de Vega; Miriam Mateos; Maria Sanjurjo; Emilio Bouza; Patricia Muñoz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-04       Impact factor: 3.267

3.  Candida albicans Germ-Tube Antibody: Evaluation of a New Automatic Assay for Diagnosing Invasive Candidiasis in ICU Patients.

Authors:  Manuel Parra-Sánchez; Ismail Zakariya-Yousef Breval; Carmen Castro Méndez; Silvia García-Rey; Ana Loza Vazquez; Alejandro Úbeda Iglesias; Desiree Macías Guerrero; Ana Romero Mejías; Cristobal León Gil; Estrella Martín-Mazuelos
Journal:  Mycopathologia       Date:  2017-04-04       Impact factor: 2.574

4.  ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients.

Authors:  Ignacio Martin-Loeches; Massimo Antonelli; Manuel Cuenca-Estrella; George Dimopoulos; Sharon Einav; Jan J De Waele; Jose Garnacho-Montero; Souha S Kanj; Flavia R Machado; Philippe Montravers; Yasser Sakr; Maurizio Sanguinetti; Jean-Francois Timsit; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2019-03-25       Impact factor: 17.440

5.  Prospective Evaluation of Serum β-Glucan Testing in Patients With Probable or Proven Fungal Diseases.

Authors:  Cécile Angebault; Fanny Lanternier; Frédéric Dalle; Cécile Schrimpf; Anne-Laure Roupie; Aurélie Dupuis; Aurélie Agathine; Anne Scemla; Etienne Paubelle; Denis Caillot; Bénédicte Neven; Pierre Frange; Felipe Suarez; Christophe d'Enfert; Olivier Lortholary; Marie-Elisabeth Bougnoux
Journal:  Open Forum Infect Dis       Date:  2016-06-16       Impact factor: 3.835

6.  (1→3)-β-D-Glucan Levels Correlate With Neurocognitive Functioning in HIV-Infected Persons on Suppressive Antiretroviral Therapy: A Cohort Study.

Authors:  Martin Hoenigl; Michelli Faria de Oliveira; Josué Pérez-Santiago; Yonglong Zhang; Sheldon Morris; Allen J McCutchan; Malcolm Finkelman; Thomas D Marcotte; Ronald J Ellis; Sara Gianella
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Combined use of serum (1,3)-β-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units.

Authors:  Daniele Roberto Giacobbe; Malgorzata Mikulska; Mario Tumbarello; Elisa Furfaro; Marzia Spadaro; Angela Raffaella Losito; Alessio Mesini; Gennaro De Pascale; Anna Marchese; Marco Bruzzone; Paolo Pelosi; Michele Mussap; Alexandre Molin; Massimo Antonelli; Brunella Posteraro; Maurizio Sanguinetti; Claudio Viscoli; Valerio Del Bono
Journal:  Crit Care       Date:  2017-07-10       Impact factor: 9.097

8.  Biomarkers of fungal infection: Expert opinion on the current situation.

Authors:  E Bouza; B Almirante; J García Rodríguez; J Garnacho-Montero; M Salavert; P Muñoz; M Sanguinetti
Journal:  Rev Esp Quimioter       Date:  2019-11-14       Impact factor: 1.553

9.  Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions.

Authors:  Cristóbal León; Sergio Ruiz-Santana; Pedro Saavedra; Carmen Castro; Ana Loza; Ismail Zakariya; Alejandro Úbeda; Manuel Parra; Desirée Macías; José Ignacio Tomás; Antonio Rezusta; Alejandro Rodríguez; Frederic Gómez; Estrella Martín-Mazuelos
Journal:  Crit Care       Date:  2016-05-16       Impact factor: 9.097

10.  (1,3)-β-D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial.

Authors:  Gennaro De Pascale; Brunella Posteraro; Sonia D'Arrigo; Giorgia Spinazzola; Rita Gaspari; Giuseppe Bello; Luca Maria Montini; Salvatore Lucio Cutuli; Domenico Luca Grieco; Valentina Di Gravio; Giulia De Angelis; Riccardo Torelli; Elena De Carolis; Mario Tumbarello; Maurizio Sanguinetti; Massimo Antonelli
Journal:  Crit Care       Date:  2020-09-05       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.